New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...

Do you continue daratumumab beyond 24 months in first line treatment of amyloidosis?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Rochester

This is an important and common clinical question, and one for which prospective data are currently limited. For background, the ANDROMEDA clinical trial (Kastritis et al., PMID 34192431) demonstrated that the addition of daratumumab to cyclophosphamide, bortezomib, and dexamethasone (CyBorD) signif...

Would you consider upfront, time-limited anti-IL-5 therapy for I-HES or L-HES to avoid steroid side effects?

1 Answers

Mednet Member
Mednet Member
Hematology · Dalhousie University, Canada

There are two parts to this question: Are there better options than steroids for the treatment of iHES and L-HES? The answer is an emphatic yes. These are chronic diseases, and steroids are really not the optimal therapy. IL-5 inhibitors such as mepolizumab and benralizumab are effective in reducing...

If a pregnant patient with a mechanical heart valve takes warfarin throughout her pregnancy, what are the chances that the fetus will be harmed?

1 Answers

Mednet Member
Mednet Member
Cardiology · University of Southern California

Warfarin is effective for thromboembolic prevention in pregnant patients with mechanical valves. There is however an overwhelming evidence that warfarin taken during pregnancy is deleterious to the fetus. Its use during the first 6–12 weeks of gestation can be associated with important fetal complic...

Would you recommend ISRT for an initially bulky nodular lymphocyte predominant Hodgkin lymphoma with complete metabolic response after 4 cycles of R-CHOP?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma. Approximately 95% of Hodgkin lymphoma cases are classified as classic Hodgkin lymphoma, including the nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes, all of which a...

Do you offer IV iron first line to women with iron deficiency anemia from heavy menstrual bleeding?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

I offer first-line IV iron because oral iron cannot keep up with the losses from heavy menstrual bleeding, and the majority can't tolerate it. I routinely give a gram of LMW iron dextran in one hour, Feraheme (not ferumoxytol generic) 1,020 mg in 30 minutes, or ferric derisomaltose 1 gram in 30 minu...

Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Northwestern University

Extramedullary disease such as CNS involvement is quite uncommon at diagnosis in acute promyelocytic leukemia (APL). However, it can be seen in patients with relapsed disease. Both isolated CNS relapse and CNS relapse associated with morphologic or molecular relapse can occur. Yet one has the impres...

What dose of radiotherapy do you use for low volume Castleman's disease?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · MD Anderson Cancer Center

Reports in the literature are varied in terms of radiation dose. For scenarios such as this with low volume disease, it is probably reasonable to consider the lower end of ranges reported by others to be successful, such as 30 Gy. Careful pathology review is important for these cases as well. One mu...

Do you check IGHV mutation status in patients with newly diagnosed CLL?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Kansas Cancer Center

Yes. In the targeted therapy era, there are three factors that continue to have prognostic and therapeutic significance and should be checked: IgHV mutation status p53 aberrancy - requires both FISH for del17p AND mutation analysis for p53 Complex karyotype - can be done on peripheral blood or marr...

Would you radiate the thoracic duct for bilateral chylothorax in a hematologic malignancy with no discrete adenopathy?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We have done for adenopathy, which relieves obstruction and thus helps with drainage, but we don’t know how it would help in this situation.